Yale Liver Center Research Seminar

Presented by Yale School of Medicine,
Department of Internal Medicine

Changing Epidemiology of Hepatocellular Cancer

Fasiha Kanwal, MD, MSHS
Professor of Medicine
Chief, Section of Gastroenterology and Hepatology
Baylor College of Medicine

Tuesday, April 5, 2022 | 5:00-6:00PM

https://zoom.us/j/93397134325?pwd=TE0xYy9MdHBTUEVucE5UeTluRkpZZz09&from=addon
Meeting ID: 933 9713 4325
Passcode: 088174

Host: Mario Strazzabosco, MD, PhD
Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (29442) to 203-442-9435.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Target Audience: YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity. Needs assessment: Published studies show a shift in the trends in hepatocellular cancer (HCC) incidence.1,2 Two populations of patients who are commonly seen in routine hepatology practice and who are at a high risk for HCC in the U.S. include patients with cured hepatitis C virus infection and patients with nonalcoholic fatty liver disease.3-5 Data show deficits in risk stratification and early detection of HCC. Information about current trends and burden of HCC and its risk factors can inform clinical decision making around risk assessment and risk stratification.

Objectives:
1. Current trends in HCC incidence;
2. Discuss two populations at high risk for HCC in the U.S including patients with cured hepatitis C virus infection and those with nonalcoholic fatty liver disease;
3. Discuss the recommendations for secondary prevention of HCC, including HCC surveillance in high-risk patients.

Faculty Disclosures:
F. Kanwal, faculty/planner for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose. M. Strazzabosco, faculty/planner for this educational event, is a consultant for Engitix. All of the relevant financial relationships listed for these individuals have been mitigated. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. This course will fulfill the licensure requirement set forth by the State of Connecticut.